Fujifilm Biotechnologies has inaugurated an advanced manufacturing center in Teesside, U.K., reinforcing its position as a leader in contract development and manufacturing for biologics, vaccines, and advanced therapies. This expansion, fueled by a substantial investment of approximately £400 million from FUJIFILM Corporation, Japan, includes the establishment of the U.K.’s largest single-use biopharmaceutical facility.
Expanded Manufacturing Capacity
The new facility will feature both 2,000 L and 5,000 L single-use bioreactors, providing a total production capacity of up to 19,000 L. This setup allows for small- and mid-scale antibody manufacturing, with the versatility to adapt to varying customer needs. The 110,000 square-foot facility is expected to commence operations in early 2026, enhancing Fujifilm’s ability to meet the growing demand for innovative treatment options.
Bioprocess Innovation Centre
In tandem with the manufacturing facility, Fujifilm has launched the Bioprocess Innovation Centre UK (BIC UK). This state-of-the-art laboratory is designed for high-throughput and continuous process development. Spanning over 102,200 square feet, the center effectively doubles the existing laboratory space, while complementing the enhanced Good Manufacturing Practice (GMP) capabilities of the site.
Advancing Global Supply Chain Agility
These strategic investments are pivotal in enhancing the supply chain agility of Fujifilm’s global manufacturing network. The facilities are geared toward developing and producing complex medicines for a range of conditions, including cancer, neurodegenerative diseases, and rare disorders. Through the innovative kojoX™ modular approach, Fujifilm aims to harmonize technology and processes, facilitating seamless technology transfer between its facilities in the U.K. and Toyama, Japan.
Commitment to Growth
Toshihisa Iida, a prominent figure at Fujifilm Corporation, emphasized the company’s commitment to expanding its CDMO business, having invested over £5 billion globally over the past decade. This latest expansion will enable Fujifilm to support various product stages, from early clinical manufacturing to low-volume therapies targeted at ultra-rare diseases, all within a single facility.
Community and Government Engagement
The grand opening event was attended by distinguished guests, including His Royal Highness The Duke of Edinburgh and other notable public officials. Their presence underscores the significance of this development not only for Fujifilm but also for local and national stakeholders in the life sciences sector. Lars Petersen, CEO of Fujifilm Biotechnologies, highlighted the benefits of enhanced scalability and technology transfer for pharmaceutical and biotechnology partners.
Building Future Talent
Jonathan Haigh, senior vice president at Fujifilm Biotechnologies, acknowledged the contributions of the organization’s workforce and community partners. With over 960 employees at the U.K. site, Fujifilm is committed to nurturing talent through academic partnerships with prominent universities. This initiative aims to support the life sciences ecosystem and foster the next generation of specialists in STEM and advanced manufacturing.
Revolutionary Processing Solutions
The new facility will also incorporate the innovative SymphonX™ downstream processing skid, designed to streamline all downstream unit operations across varying scales. This revolutionary equipment enhances the flexibility of scaling in both fed-batch and continuous processes, thus improving operational efficiency.
A Key Player in the UK Economy
Fujifilm Biotechnologies’ U.K. site is part of a broader global workforce of 5,000, contributing significantly to the economy. FUJIFILM Corporation maintains a diverse presence in the U.K., employing 1,700 individuals across multiple sectors, including life sciences. This multifaceted engagement positions Fujifilm as a crucial partner in supporting the National Health Service (NHS) and advancing healthcare solutions.
In conclusion, the opening of Fujifilm Biotechnologies’ new manufacturing center in the U.K. marks a significant milestone in biopharmaceutical development. This expansion not only enhances local capabilities but also strengthens global manufacturing networks. As Fujifilm continues to invest in advanced technologies and talent, it sets a precedent for innovation in the life sciences sector.
Key Takeaways:
- Fujifilm Biotechnologies invests £400 million in a new manufacturing center in Teesside, U.K.
- The facility will feature advanced single-use bioreactors with a total capacity of up to 19,000 L.
- The Bioprocess Innovation Centre UK will serve as a hub for process development and innovation.
- Fujifilm’s commitment to growth includes over £5 billion invested globally in the past decade.
- The expansion aims to enhance scalability and technology transfer for pharmaceutical partners.
Read more → www.chemengonline.com